The Front Room — a clinical regulatory commons
RSS
GUIDANCE Final

CDE Guidance on Centralised Monitoring

NMPA · 2024 National Medical Products Administration
ABSTRACT — EDITORS' SUMMARY

NMPA Centre for Drug Evaluation guidance on centralised monitoring practice in Chinese trials.

EXTERNAL LINK
EXTERNAL LINK www.cde.org.cn
↗
METADATA
TypeGUIDANCE
Year2024
VersionFinal
StatusCurrent
FormatLINK
Pages—
Size—
Last reviewedMAY 2024
SOURCE
LINK · CANONICAL LINK https://www.cde.org.cn/main/news/ ↗
RELATED · SAME AUTHORITY
NMPA NMPA Announcement No. 125 of 2025
NMPA Announcement on Adoption of ICH E6(R3) Good Clinical Practice Guideline
NOTICE 2025
NMPA CDE, November 2025
Guiding Principles for Computerized Systems and Electronic Data in Drug Clinical Trials (Draft for Comment)
GUIDANCE 2025
NMPA 2025
Good Clinical Practice for Drugs (2025 Revision — Draft for Comments)
REGULATION 2025
NMPA 2025
Inspection Checkpoints and Judging Principles for Drug Clinical Trials
INSPECTION PROCEDURE 2025
NMPA No. 31 of 2024
Technical Guidelines for Evaluation of the Relevance of Adverse Events in Drug Clinical Trials
GUIDANCE 2024